TY - JOUR
T1 - New Therapeutics for Ulcerative Colitis
AU - Hirten, Robert P.
AU - Sands, Bruce E.
N1 - Funding Information:
R.P.H. discloses consulting fees from HealthMode, Inc.; Janssen Pharmaceuticals; and Takeda Pharmaceuticals, as well as research support from Intralytix, Inc., and a Crohn’s and Colitis Foundation Career Development Award (grant number 607934). B.E.S. discloses consulting fees from 4D Pharma, Abbvie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Boston Pharmaceuticals, Capella Biosciences, Celgene, Celltrion Healthcare, EnGene, Ferring, Genentech, Gilead, Hoffmann-La Roche, Immunic, Ironwood Pharmaceuticals, Janssen Pharmaceuticals, Eli Lilly, Lyndra, MedImmune, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer, Progenity, Prometheus Laboratories, Redhill Biopharma, Rheos Medicines, Seres Therapeutics, Shire, Synergy Pharmaceuticals, Takeda Pharmaceuticals, Target PharmaSolutions, Theravance Biopharma R&D, TiGenix, and Vivelix Pharmaceuticals; honoraria for speaking in Continuing Medical Education programs from Takeda Pharmaceuticals, Janssen Pharmaceuticals, Eli Lilly, Gilead, Pfizer, and Genetech; and research funding from Celgene, Pfizer, Takeda Pharmaceuticals, Theravance Bio-pharma R&D, and Janssen Pharmaceuticals.
Publisher Copyright:
© 2021 by Annual Reviews. All rights reserved.
PY - 2021/1/27
Y1 - 2021/1/27
N2 - Ulcerative colitis (UC) is a relapsing and remitting inflammatory disease of the colon with a variable course. Despite advances in treatment, only approximately 40% of patients achieve clinical remission at the end of a year, prompting the exploration of new treatment modalities. This review explores novel therapeutic approaches to UC, including promising drugs in various stages of development, efforts to maximize the efficacy of currently available treatment options, and non-medication-based modalities. Treatment approaches which show promise in impacting the future of UC management are highlighted.
AB - Ulcerative colitis (UC) is a relapsing and remitting inflammatory disease of the colon with a variable course. Despite advances in treatment, only approximately 40% of patients achieve clinical remission at the end of a year, prompting the exploration of new treatment modalities. This review explores novel therapeutic approaches to UC, including promising drugs in various stages of development, efforts to maximize the efficacy of currently available treatment options, and non-medication-based modalities. Treatment approaches which show promise in impacting the future of UC management are highlighted.
KW - Crohn's disease
KW - Ulcerative colitis
KW - anti-adhesion therapy
KW - anti-interleukin inhibitor
KW - inflammatory bowel disease
KW - janus kinase inhibitor
KW - sphingosine receptor modulator
UR - http://www.scopus.com/inward/record.url?scp=85100156284&partnerID=8YFLogxK
U2 - 10.1146/annurev-med-052919-120048
DO - 10.1146/annurev-med-052919-120048
M3 - Review article
C2 - 33502898
AN - SCOPUS:85100156284
SN - 0066-4219
VL - 72
SP - 199
EP - 213
JO - Annual Review of Medicine
JF - Annual Review of Medicine
ER -